DNMT3A KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon4 and 1 bp insertion in exon4.
DNA (cytosine 5) methyltransferase 3 alpha, DNA (cytosine-5)-methyltransferase 3A, DNA MTase HsaIIIA, DNA cytosine methyltransferase 3A2, DNA methyltransferase 3 alpha, DNA methyltransferase 3a, DNA methyltransferase HsaIIIA, DNM3A_HUMAN, DNMT, DNMT 3a, DNMT3A2, M.HsaIIIA, MCMT, OTTHUMP00000201149, TBRS
DNMT3A KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon4 and 1 bp insertion in exon4.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Lane 2: DNMT3A knockout HeLa cell lysate (20 μg)
Lane 3: HEK-293 cell lysate (20 μg)
Lane 4: Daudi cell lysate (20 μg)
Lanes 1-4: Merged signal (red and green). Green - Anti-Dnmt3a antibody [EPR18455-94] ab227823 observed at 125 kDa. Red - loading control Anti-GAPDH antibody [6C5] - Loading Control ab8245 observed at 37 kDa.
Anti-Dnmt3a antibody [EPR18455-94] ab227823 Anti-Dnmt3a antibody [EPR18455-94] was shown to specifically react with Dnmt3a in wild-type HeLa cells. Loss of signal was observed when knockout cell line Human DNMT3A knockout HeLa cell line ab261793 (knockout cell lysate ab257128) was used. Wild-type and Dnmt3a knockout samples were subjected to SDS-PAGE. Anti-Dnmt3a antibody [EPR18455-94] ab227823 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-Dnmt3a antibody [EPR18455-94] (Anti-Dnmt3a antibody [EPR18455-94] ab227823) at 1/1000 dilution
Lane 1: Wild-type HeLa cell lysate at 20 µg
Lane 2: Dnmt3a knockout HeLa cell lysate at 20 µg
Lane 2: Western blot - Human DNMT3A knockout HeLa cell line (Human DNMT3A knockout HeLa cell line ab261793)
Lane 3: HEK-293 cell lysate at 20 µg
Lane 4: Daudi cell lysate at 20 µg
All lanes: Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) at 1/20000 dilution
Performed under reducing conditions.
Predicted band size: 102 kDa
Observed band size: 125 kDa
Lane 2: DNMT3A knockout HeLa cell lysate (20 μg)
Lane 3: HEK-293 cell lysate (20 μg)
Lane 4: Daudi cell lysate (20 μg)
Lanes 1-4: Merged signal (red and green). Green - Anti-Dnmt3a antibody [EPR18455] ab188470 observed at 125 kDa. Red - loading control Anti-GAPDH antibody [6C5] - Loading Control ab8245 observed at 37 kDa.
Anti-Dnmt3a antibody [EPR18455] ab188470 Anti-Dnmt3a antibody [EPR18455] was shown to specifically react with Dnmt3a in wild-type HeLa cells. Loss of signal was observed when knockout cell line Human DNMT3A knockout HeLa cell line ab261793 (knockout cell lysate ab257128) was used. Wild-type and Dnmt3a knockout samples were subjected to SDS-PAGE. Anti-Dnmt3a antibody [EPR18455] ab188470 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) were incubated overnight at 4°C at 1 in 2000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-Dnmt3a antibody [EPR18455] (Anti-Dnmt3a antibody [EPR18455] ab188470) at 1/2000 dilution
Lane 1: Wild-type HeLa cell lysate at 20 µg
Lane 2: Dnmt3a knockout HeLa cell lysate at 20 µg
Lane 2: Western blot - Human DNMT3A knockout HeLa cell line (Human DNMT3A knockout HeLa cell line ab261793)
Lane 3: HEK-293 cell lysate at 20 µg
Lane 4: Daudi cell lysate at 20 µg
All lanes: Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) at 1/20000 dilution
Performed under reducing conditions.
Predicted band size: 102 kDa
Observed band size: 125 kDa
Allele-1: 1 bp deletion in exon4
Allele-2: 1 bp insertion in exon4
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com